AppBlogHilfeonvista bank
Werbung ausblenden

News zu NANOBIOTIX S.A. SP.ADR

ROUNDUP/Aktien New York Schluss: Dow legt nach trister Vorwoche wieder etwas zu · Uhr · dpa-AFX
Aktien New York: Kaum Bewegung - Zinssorgen bleiben im Fokus · Uhr · dpa-AFX
ROUNDUP/Aktien New York: Kaum Bewegung - Zinssorgen bleiben im Fokus · Uhr · dpa-AFX
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital · Uhr · Business Wire
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer · Uhr · Business Wire
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4 · Uhr · Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital · Uhr · Business Wire
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets · Uhr · Business Wire
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer · Uhr · Business Wire
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022 · Uhr · Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital · Uhr · Business Wire
NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference · Uhr · Business Wire
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination · Uhr · Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital · Uhr · Business Wire
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference · Uhr · Business Wire
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy · Uhr · Business Wire
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
NANOBIOTIX Provides Third Quarter Operational and Financial Update · Uhr · Business Wire
Werbung ausblenden